Supporting the Centillion-led team, Pace® will help the design, development and manufacturing roll-out of an integrated platform built for patients with rare and ultra-rare genetic diseases
MINNEAPOLIS, MN – November 12, 2026 – For people living with rare and ultra-rare diseases, traditional drug manufacturing models aren’t built for personalized genetic medicine. Pace® Life Sciences, a division of Pace®, a Science and Technology Company, today announced its participation in a consortium led by Centillion Biosciences, Inc. selected by the Advanced Research Projects Agency for Health (ARPA-H) under its Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program to address the high cost of manufacturing these medications and improve accessibility for all who need them.
Read Full Article Here.